ONO-1110 + Placebo

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hunner Type Interstitial Cystitis

Conditions

Hunner Type Interstitial Cystitis

Trial Timeline

Apr 2, 2025 → Aug 1, 2026

NCT ID

NCT06752603

About ONO-1110 + Placebo

ONO-1110 + Placebo is a phase 2 stage product being developed by Ono Pharmaceutical for Hunner Type Interstitial Cystitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06752603. Target conditions include Hunner Type Interstitial Cystitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06752603	Phase 2	Recruiting	Apr 2, 2025	Aug 1, 2026	Hunner Type Interstitial Cystitis
NCT06752590	Phase 2	Recruiting	Mar 26, 2025	Sep 1, 2026	Fibromyalgia
NCT06708416	Phase 2	Active	Feb 12, 2025	Aug 31, 2026	Postherpetic Neuralgia
NCT06805565	Phase 2	Active	Jan 16, 2025	Oct 31, 2026	Social Anxiety Disorder (SAD)
NCT06792136	Phase 2	Active	Jan 16, 2025	Aug 31, 2026	Major Depressive Disorder (MDD

Other Products from Ono Pharmaceutical

Sivelestat sodium hydrate + Sivelestat sodium hydrateApproved

Abatacept + Placebo matching with Abatacept + MethotrexateApproved

Rivastigmine transdermal patchApproved

Sitagliptin phosphatePhase 3

ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + PlaceboPhase 3